

BD GeneOhm™ StaphSR

Rapid, simultaneous identification of MRSA and SA from positive blood culture

Site	MRSA ¹		SA	
	Positive Agreement	Negative Agreement	Positive Agreement	Negative Agreement
1	100.0%	98.7%	100.0%	100.0%
2	100.0%	98.2%	100.0%	98.9%
3	100.0%	100.0%	100.0%	100.0%
4	100.0%	98.3%	98.8%	96.5%
5	100.0%	100.0%	100.0%	100.0%

¹ BD GeneOhm™ package insert, BD Diagnostics, 2008

Bacterial bloodstream infections (BSIs) are a leading cause of morbidity and mortality worldwide.² Staphylococcus aureus related bacteremia are associated with increased mortality up to 60%.³

"Inappropriate initial therapy to treat S. aureus bloodstream infections has been associated with increased patient mortality."⁴

The median hospital charge for methicillin resistant S. aureus (MRSA) and methicillin sensitive S. aureus (MSSA) bacteremia were \$26,424 and \$19,212, respectively. In addition, these infections resulted in an increased length of stay of 9 and 7 days, respectively.⁵

² Reimer, L. G., Wilson, M. L. & Weinstein, M. P. (1997). Update on detection of bacteremia and fungemia. *Clinical Microbiology Reviews* 10, 444-65.

³ Mylotte, J. M. & Tayara, A. (2000). Blood cultures: clinical aspects and controversies. *European Journal of Microbiology and Infectious Diseases* 19, 157-63

⁴ Khatib et al Impact of initial antibiotic choice and delayed appropriate treatment on the outcome of Staphylococcus aureus bacteremia *Eur J Clin Microbiol Infect Dis* (2006) 181-185.

⁵ Cosgrove et al Impact of Methicillin Resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. *ICHE* (2005) 166-174.

BD GeneOhm™ StaphSR

Clinical Advantages:

- Rapid identification and treatment of BSIs has been proven to reduce healthcare costs and improve patient outcomes⁶
- Promotes faster, better antibiotic selection
- Facilitates earlier isolation of patients infected with MRSA to prevent further transmission and infection

Assay Features:

- Rapid, simultaneous identification and differentiation of MRSA and SA direct from positive blood culture bottles
- 2 hour laboratory results vs. 2-3 days required for traditional microbiology culture methods
- Simple user-friendly workflow
 - Less labor intensive compared to traditional microbiology algorithms
- Aids in the differentiation of MRSA/SA and potential contaminants such as Coagulase Negative *Staphylococci*

*The BD GeneOhm™ StaphSR Assay is the first test to simultaneously identify and differentiate MRSA and SA directly from positive blood culture. This simple and fast assay enables physicians to implement the **right treatment at the right time** for patients with bloodstream infections, **transforming patient care™** and significantly reducing healthcare costs.*



BD Diagnostics
6146 Nancy Ridge Drive
San Diego, California 92121
www.bd.com/geneohm
888-GENEOHM

BD
2771 Bristol Circle
Oakville, ON
L6H 6R5
Canada
800-268-5430

BD, BD logo and all other trademarks are property of Becton, Dickinson and Company.
Copyright © 2007 BD
Patent protection pending

⁶ Barenfager, J. et al Clinical and financial benefits of rapid bacterial identification and antimicrobial susceptibility testing. *Journal of Clin Micro* (1999) 1415-1418

The BD GeneOhm™ line of products have been developed to help improve patient outcomes by delivering cost-effective, rapid molecular solutions for the prevention and identification of healthcare-associated infections (HAIs).